1 Department of Dynamic and Clinical Psychology, and Health Studies, Sapienza University of Rome, Rome, Italy 2 Institute of Cognitive Sciences and Technologies, Italian National Research Council, ...

Tired of generic logos? We dissect 30 abstract logos like Nike's and Spotify's to reveal why they're so powerful. This is a no-nonsense guide for entrepreneurs on using abstract shapes to build an ...

Cartoonists and educators Shay Mirk and Eleri Harris have teamed up once again. They were editorial colleagues at the late, lamented the Nib—the long-running influential hub for graphic nonfiction and ...

After primarily focusing on private conversations since its founding, Snapchat is embracing public conversations with a new “Topic Chats” feature. The social network says the feature lets users chat ...

As the Oklahoma City Thunder continue to look like the NBA's undisputed best team, Nikola Topic has dealt with a personal matter away from the team. Sam Presti announced on Oct. 30 that he was ...

Nonrenewable energy sources like fossil fuels are being depleted and will eventually run out. 91% of U.S. energy in 2023 came from nonrenewable sources including petroleum and natural gas. Despite ...

We invite researchers to submit abstracts for oral presentations in the field of medicinal chemistry, focusing on the latest innovations in drug design, discovery, and development. Topics of… Read ...

Oklahoma City Thunder guard Nikola Topic is undergoing chemotherapy after being diagnosed with testicular cancer, the team announced Thursday. Topic, a first-round draft pick in the 2024 NBA Draft, ...

Oklahoma City Thunder guard Nikola Topic has been diagnosed with testicular cancer and is undergoing chemotherapy. Sam Presti, the team’s general manager, announced the diagnosis on Thursday. Topic ...

Foreign Minister of Russia Sergei Lavrov. (Image by Kremlin.ru) Undoubtedly, after several tectonic praises for Africa, the continental organization (African Union) and its regional economic blocs, ...

LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking presentations showcasing the results of a Phase 2b dose finding trial evaluating the efficacy and safety of ...